Search

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

Generalized Pustular Psoriasis: Impact Beyond the Skin

Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

Country Management Committee: A Message | Boehringer Ingelheim US

Click here to read a statement from Boehringer Ingelheim on the tragic events in Uvalde, TX and how BI Cares is supporting victims and families.

PolyMast Mastitis Tube Introduced | Boehringer Ingelheim US

Find out more about the new name in the mastitis tube market, cutting down today's regular 5-day treatment to just 3: PolyMast from Boehringer Ingelheim.

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.

Financial health

We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Supply Chain Scholarship for Cowtribe

A supply chain course we sponsored boosted the career of Latifa Saaka

Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program

Could decentralised trials transform the way we view depression?

Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.

Outside the lab…inside the family

We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.

Niha Agarwalla

My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!

Our Stories

Life forward - Boehringer Ingelheim unveils its evolved company brand

New initiative elevates the importance of CKD testing

Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Science Stories

Financial year 2018

Help in all situations in life

Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".

Schizophrenia: Trial Results Show Advance in Cognition | BI US

Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

Open Innovation at Boehringer Ingelheim

Science & Innovation

Our Science

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Generalized Pustular Psoriasis: Impact Beyond the Skin

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

Country Management Committee: A Message | Boehringer Ingelheim US

PolyMast Mastitis Tube Introduced | Boehringer Ingelheim US

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Financial health

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Supply Chain Scholarship for Cowtribe

Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program

Could decentralised trials transform the way we view depression?

Outside the lab…inside the family

Niha Agarwalla

Our Stories

Life forward - Boehringer Ingelheim unveils its evolved company brand

New initiative elevates the importance of CKD testing

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Science Stories

Financial year 2018

Help in all situations in life

Schizophrenia: Trial Results Show Advance in Cognition | BI US

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

Open Innovation at Boehringer Ingelheim

Science & Innovation